Device Trial Radar · NCT07783906
Precision Closed-loop Brain-Computer Interface Neuromodulation for Treatment-Resistant Depression
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Shanghai Mental Health CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Xuanwu Hospital, Beijing; Anding Hospital, Beijing
- First posted
- Aug 25, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether precision closed-loop neuromodulation treatments can improve depressive symptoms and daily functioning in people with treatment-resistant major depressive disorder (TRD). The study will assess the effectiveness and safety of two neuromodulation approaches: closed-loop deep brain stimulation (DBS) and transcutaneous auricular vagus nerve stimulation (taVNS). Treatment-resistant major depressive disorder refers to depression that does not improve sufficiently after adequate treatment with standard antidepressant therapies. This study focuses on people with TRD, including individuals with early-onset depression, a history of self-harm or suicidal thoughts, or depression associated with traumatic experiences. This study aims to answer whether closed-loop DBS and taVNS can reduce depressive symptoms compared with sham stimulation, whether these treatments are safe and well tolerated, and whether changes in brain activity are associated with clinical improvement. This is a multicenter, prospective clinical study conducted at Shanghai Mental Health Center, Beijing Anding Hospital, and Xuanwu Hospital. Eligible participants with TRD will receive either DBS or taVNS according to patient preference. Within each intervention group, participants will be randomly assigned to active stimulation or sham stimulation groups to assess treatment effects. During the study, participants will receive neuromodulation treatment and complete regular follow-up assessments. These assessments will include evaluation of depressive symptoms, anxiety symptoms, cognitive function, social functioning, brain electrical activity using electroencephalography (EEG), brain imaging using magnetic resonance imaging (MRI), and monitoring of adverse events. The study will compare changes in clinical symptoms, brain-related measures, and safety outcomes between active and sham stimulation groups. The findings may help determine whether precision neuromodulation approaches can provide a new treatment option for people with treatment-resistant major depressive disorder.
Conditions
- Treatment-Resistant Major Depressive Disorder
- Major Depressive Disorder
Interventions
Closed-loop Deep Brain Stimulation (DBS)Device
Closed-loop deep brain stimulation (DBS) is an implanted neuromodulation intervention that delivers electrical stimulation based on real-time neural signals. Participants assigned to the DBS pathway will undergo implantation of a DBS system and receive either active or delayed stimulation according to the randomized study assignment. Clinical outcomes, cognitive function, brain activity, and safety outcomes will be assessed during follow-up.
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)Device
Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation intervention that delivers electrical stimulation through electrodes placed on auricular sites associated with the vagus nerve. Participants assigned to the taVNS pathway will receive either active or sham stimulation according to the randomized study assignment. Clinical outcomes, cognitive function, brain activity, and safety outcomes will be assessed during follow-up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in 17-item Hamilton Rating Scale for Depression (HAMD-17) scoreTime frame: Baseline to Week 8
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.